48 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.
Kezar Life Sciences
Structure-based design of฿1i or฿5i specific inhibitors of human immunoproteasomes.
Leiden Institute of Chemistry and Netherlands Proteomics Centre
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.
Weill Cornell Medical College
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
Hokkaido University
Molecular mechanisms of acquired proteasome inhibitor resistance.
University of California San Diego
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Proteolix
Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
Chinese Academy of Medical Sciences and Peking Union Medical College
Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.
Zhejiang University
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (?5i).
Merck
Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.
Weill Cornell Medicine
Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp.
Kumamoto University
Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT).
Novartis Institutes For Biomedical Research
Discovery of Anticancer Agents of Diverse Natural Origin.
University of Illinois At Chicago
Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
Chinese Academy of Sciences
Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Zhejiang University
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
University of Kentucky
Structure-Based Design of Selective LONP1 Inhibitors for Probing
Genomics Institute of The Novartis Research Foundation
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Nanjing Normal University
Discovery of selective fragment-sized immunoproteasome inhibitors.
Hungarian Academy of Sciences
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Tsinghua University
Structure-Activity Relationships of Noncovalent Immunoproteasome ?5i-Selective Dipeptides.
Weill Cornell Medicine
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
The University of Melbourne
Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Hangzhou Xixi Hospital
LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.
University of Kentucky
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.
Roche Pharma Research and Early Development
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Hangzhou Institute of Innovative Medicine
Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
Zhejiang University
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Kezar Life Sciences
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Hangzhou Xixi Hospital
Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.
Purdue University
Structure-Based Design of Inhibitors Selective for Human Proteasome ?2c or ?2i Subunits.
Leiden Institute of Chemistry and Netherlands Proteomics Centre
Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations.
University of Auckland
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
Purdue University
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Zhejiang University
Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.
Kumamoto University
Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete.
Intermed Discovery Gmbh (Imd)
Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.
Numazu Bio-Medical Research Institute
Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
Novartis Pharma
Design, synthesis, and evaluation of cystargolide-based ?-lactones as potent proteasome inhibitors.
New Mexico Institute of Mining and Technology
Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Universit£
Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.
Monash University
Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.
University of Glasgow
